NCT00420680View on ClinicalTrials.gov

Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934)

PHASE3CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

November 7, 2005

Primary Completion Date

August 1, 2006

Study Completion Date

August 1, 2006

Conditions
Anesthesia
Interventions
DRUG

Sugammadex

Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium

DRUG

Sugammadex

Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.

DRUG

Placebo

Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00420680 - Safety and Efficacy Evaluation of Sugammadex in Cardiac Patients (19.4.309)(P05934) | Biotech Hunter | Biotech Hunter